Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
暂无分享,去创建一个
L. Lund | J. Curtis | Yongfei Wang | K. Dharmarajan | A. Maggioni | T. Dardas | U. Dahlström | K. Bilchick | U. Sartipy | W. Levy | I. Anand | A. Cheng | R. Shadman | C. O'connor
[1] A. Brandes,et al. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. , 2019, JACC. Heart failure.
[2] R. Porcher,et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. , 2019, Circulation.
[3] George A. Johnson,et al. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. , 2018, JACC. Clinical electrophysiology.
[4] K. Swedberg,et al. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. , 2017, Journal of the American College of Cardiology.
[5] C. O'connor,et al. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? , 2017, JACC. Clinical electrophysiology.
[6] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[7] D. Mozaffarian,et al. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. , 2015, Heart rhythm.
[8] Mark A Hlatky,et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Circulation.
[9] U. Dahlström,et al. Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.
[10] Wojciech Zareba,et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.
[11] D. Mozaffarian,et al. Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.
[12] A. di Lenarda,et al. [Italian Network on Congestive Heart Failure: ten-year experience]. , 2006, Giornale italiano di cardiologia.
[13] P. Poole‐Wilson,et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). , 2006, Journal of the American College of Cardiology.
[14] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[15] J. Spertus,et al. Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. , 2004, The American journal of cardiology.
[16] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[17] D. Delurgio,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[18] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[19] C M O'Connor,et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.